InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.052 0.005 (10.64%)+
Announcement
Release
30 Jul 2026 8:24AM
Price at Release
$0.047
Full Release
download
Summary
Immutep Limited, a biotechnology company developing novel immunotherapies for cancer and autoimmune diseases, released its quarterly activities report and Appendix 4C for the quarter ending June 30, 2026. The company highlighted several key developments, including a pooled analysis of five efti trials showing a median overall survival benefit and positive results from its IMP761 LAG-3 agonist antibody trial. Despite the discontinuation of the TACTI-004 Phase III trial due to futility, Immutep remains well-funded with A$68.87 million in cash resources and is implementing cost reduction measures to extend its cash runway into the first half of 2028. The company also reported advancements in its intellectual property portfolio and ongoing investigations into the outcomes of its clinical trials.
Key Points
  • Pooled analysis of five efti trials reinforced the mechanism of action and showed a 7.7-month median overall survival benefit.
  • IMP761 LAG-3 agonist antibody showed positive first-in-human trial results.
  • Investigation into the futility outcome of the TACTI-004 trial is ongoing.
  • The company is well-funded with A$68.87 million in cash resources.
  • Cost reduction measures are underway to preserve cash runway into H1 CY2028.
  • New patents were granted, expanding the intellectual property portfolio.
  • Discontinuation of the TACTI-004 Phase III trial, but further analysis continues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.